Literature DB >> 22936825

Icatibant and ACE inhibitor angioedema.

Elizabeth Janet Illing1, Sara Kelly, Jonathan Charles Hobson, Seema Charters.   

Abstract

Icatibant is a selective bradykinin 2 receptor antagonist, currently licensed for use in hereditary angioedema. Its benefit in ACE inhibitor angioedema is yet to be fully established. A handful of preliminary case reports suggest that it may be of benefit in reducing both symptom severity and possible hospital or intensive care admission. To date, there are no case reports of the usage of Icatibant in the emergency department in the UK. Here we report our experience of Icatibant in a 62-year-old gentleman presenting with severe oral, pharyngeal and laryngeal oedema while on an ACE inhibitor.

Entities:  

Mesh：

Substances：

Year:  2012        PMID： 22936825      PMCID： PMC4543926          DOI： 10.1136/bcr-2012-006646

Source DB:  PubMed          Journal:  BMJ Case Rep        ISSN： 1757-790X


  11 in total

1.  Successful long-term treatment with the bradykinin B2 receptor antagonist icatibant in a patient with hereditary angioedema.

Authors:  Jens Greve; Thomas K Hoffmann; Patrick Schuler; Stephan Lang; Adam Chaker; Murat Bas
Journal:  Int J Dermatol       Date:  2011-10       Impact factor: 2.736

2.  Treatment of acquired angioedema with icatibant: a case report.

Authors:  Andrea Zanichelli; Matteo Badini; Ilaria Nataloni; Nicola Montano; Marco Cicardi
Journal:  Intern Emerg Med       Date:  2010-08-03       Impact factor: 3.397

3.  Angioedema due to ACE inhibitors: increased risk in patients of African origin.

Authors:  C R Gibbs; G Y Lip; D G Beevers
Journal:  Br J Clin Pharmacol       Date:  1999-12       Impact factor: 4.335

4.  Rapid resolution of erythema marginatum after icatibant in acquired angioedema.

Authors:  Anette Bygum; Sigurd Broesby-Olsen
Journal:  Acta Derm Venereol       Date:  2011-03       Impact factor: 4.437

5.  Therapeutic efficacy of icatibant in angioedema induced by angiotensin-converting enzyme inhibitors: a case series.

Authors:  Murat Bas; Jens Greve; Klaus Stelter; Henning Bier; Thomas Stark; Thomas K Hoffmann; Georg Kojda
Journal:  Ann Emerg Med       Date:  2010-05-05       Impact factor: 5.721

6.  Angiotensin-converting enzyme inhibitor-induced angioedema: a multicenter review and an algorithm for airway management.

Authors:  A G Chiu; K A Newkirk; B J Davidson; A R Burningham; E J Krowiak; Z E Deeb
Journal:  Ann Otol Rhinol Laryngol       Date:  2001-09       Impact factor: 1.547

7.  Asphyxia due to angiotensin converting enzyme (ACE) inhibitor mediated angioedema of the tongue during the treatment of hypertensive heart disease.

Authors:  D E Dean; D L Schultz; R H Powers
Journal:  J Forensic Sci       Date:  2001-09       Impact factor: 1.832

8.  Multicenter study of patients with angiotensin-converting enzyme inhibitor-induced angioedema who present to the emergency department.

Authors:  Aleena Banerji; Sunday Clark; Michelle Blanda; Frank LoVecchio; Brian Snyder; Carlos A Camargo
Journal:  Ann Allergy Asthma Immunol       Date:  2008-04       Impact factor: 6.347

9.  Angiotensin-converting enzyme inhibitors and angioedema.

Authors:  Mario Sánchez-Borges; Luis A González-Aveledo
Journal:  Allergy Asthma Immunol Res       Date:  2010-05-06       Impact factor: 5.764

10.  Icatibant.

Authors:  Emma D Deeks
Journal:  Drugs       Date:  2010       Impact factor: 9.546
View more
  7 in total

1.  Treatment of ACEI-related angioedema with icatibant: a case series.

Authors:  Maria Bova; Mar Guilarte; Anna Sala-Cunill; Paolo Borrelli; Grazia Maria Luisa Rizzelli; Andrea Zanichelli
Journal:  Intern Emerg Med       Date:  2015-02-10       Impact factor: 3.397

2.  Guidance for diagnosis and treatment of acute angioedema in the emergency department: consensus statement by a panel of Italian experts.

Authors:  Marco Cicardi; Paolo Bellis; Giuliano Bertazzoni; Mauro Cancian; Maurizio Chiesa; Paolo Cremonesi; Pietro Marino; Nicola Montano; Claudia Morselli; Francesco Ottaviani; Roberto Perricone; Massimo Triggiani; Andrea Zanichelli
Journal:  Intern Emerg Med       Date:  2013-09-04       Impact factor: 3.397

3.  Factors associated with hospitalization of patients with angiotensin-converting enzyme inhibitor-induced angioedema.

Authors:  Cheng Gang; Christopher J Lindsell; Joseph Moellman; Wesley Sublett; Kim Hart; Sean Collins; Jonathan A Bernstein
Journal:  Allergy Asthma Proc       Date:  2013 May-Jun       Impact factor: 2.587

4.  Delayed presentation of ACE inhibitor-induced angio-oedema.

Authors:  Guy Amey; Pasan Waidyasekara; Ramanathan Kollengode
Journal:  BMJ Case Rep       Date:  2013-07-29

5.  A consensus parameter for the evaluation and management of angioedema in the emergency department.

Authors:  Joseph J Moellman; Jonathan A Bernstein; Christopher Lindsell; Aleena Banerji; Paula J Busse; Carlos A Camargo; Sean P Collins; Timothy J Craig; William R Lumry; Richard Nowak; Jesse M Pines; Ali S Raja; Marc Riedl; Michael J Ward; Bruce L Zuraw; Deborah Diercks; Brian Hiestand; Ronna L Campbell; Sandra Schneider; Richard Sinert
Journal:  Acad Emerg Med       Date:  2014-04       Impact factor: 3.451

6.  Icatibant for Angiotensin-Converting Enzyme Inhibitor-Induced Angioedema in Intubated Patients: Case Series and Literature Review.

Authors:  Erin K Yeung; Haritha Saikumar; Jose Castaneda-Nerio; Sandra G Adams; Mark Wong
Journal:  Case Rep Crit Care       Date:  2018-03-04

Review 7.  Efficacy of Treatment of Non-hereditary Angioedema.

Authors:  Mignon van den Elzen; M F C L Go; A C Knulst; M A Blankestijn; H van Os-Medendorp; H G Otten
Journal:  Clin Rev Allergy Immunol       Date:  2018-06       Impact factor: 8.667
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.